# UK Recombinant Vaccines Market > UK Recombinant Vaccines Market Research Report: By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) andBy End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 16.51% - **2024:** $ 13.5 Million - **2025:** $ 15.73 Million - **2035:** $ 72.5 Million - **Key Players:** Pfizer (US), Moderna (US), Sanofi (FR), Merck (US), GSK (GB), Novavax (US), Bavarian Nordic (DK), Zydus Cadila (IN), Serum Institute of India (IN) **Report ID:** MRFR/Pharma/54239-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-recombinant-vaccines-market-56005 --- ## Market Summary ## **UK Recombinant Vaccines Market Overview****:** As per MRFR analysis, the UK Recombinant Vaccines Market Size was estimated at 15.95 (USD Million) in 2024.The UK Recombinant Vaccines Market Industry is expected to grow from 19.8(USD Million) in 2025 to 115.8 (USD Million) by 2035. The UK Recombinant Vaccines Market CAGR (growth rate) is expected to be around 17.417% during the forecast period (2025 - 2035). ### **Key UK Recombinant Vaccines Market Trends Highlighted** The UK Recombinant Vaccines Market is witnessing significant growth driven by rising vaccine demand and government initiatives aimed at enhancing public health. The ongoing need for effective immunization programs, especially in the context of global health crises like the COVID-19 pandemic, has accelerated research and development within the sector. The UK government has invested in developing and producing recombinant vaccines to bolster national immunization strategies, ensuring that new technology is swiftly translated into public health benefits.  There are ample opportunities to be explored in the UK Recombinant Vaccines Market, especially in niche segments such as veterinary vaccines and cancer immunotherapy.The increasing prevalence of infectious diseases emphasizes the need for innovative vaccine solutions. Moreover, collaborations between academic institutions and biotechnology companies represent a valuable avenue for driving advancements and commercializing novel recombinant vaccine technologies.  The UK’s robust regulatory framework regarding vaccine approval provides a conducive environment for these partnerships to flourish, potentially leading to a wider range of recombinant vaccines available to the public. Recent trends in the UK show a strong emphasis on personalized medicine, which incorporates genetic information to tailor vaccine development.This shift towards more individualized healthcare solutions is gaining traction as healthcare providers and researchers work to create vaccines that respond to the specific genetic profiles of populations.  There is also a growing focus on sustainability in vaccine production processes, aligning with the broader UK government agenda towards environmentally sustainable practices. As scientists continue to uncover new approaches, including mRNA technology and innovative adjuvants, the landscape of the Recombinant Vaccines Market in the UK is set for transformation, ultimately leading to improved public health outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **UK Recombinant Vaccines Market Drivers** ### **Growing Awareness and Acceptance of Recombinant Vaccines** The UK Recombinant Vaccines Market Industry is witnessing significant growth due to increasing awareness and acceptance of recombinant vaccines among healthcare professionals and the general public. According to Public Health England, the uptake of vaccination programs in the UK has risen dramatically, with a noted increase of over 30% in immunization rates among children in recent years. The UK government has actively promoted vaccine education campaigns, particularly focusing on new developments in recombinant technology, highlighting their safety and efficacy against various diseases.Organizations such as the National Health Service (NHS) and the British Society for Immunology have been instrumental in disseminating information, resulting in higher public confidence in recombinant vaccines. This surge in public acceptance is likely to drive the market further as more individuals opt for preventive healthcare measures by getting vaccinated, contributing to a robust demand for novel recombinant vaccines. ### **Rising Incidence of Infectious Diseases** The incidence of infectious diseases in the UK has been a crucial driver for the Recombinant Vaccines Market Industry. Recent statistics from the UK Health Security Agency highlight a 25% increase in reported cases of vaccine-preventable diseases over the past decade. This rise necessitates innovative vaccination solutions, and recombinant vaccines play a pivotal role in addressing this issue. Established organizations such as the NHS have recognized the need for expanded immunization programs, and funding allocations have been made to support the development of recombinant vaccine technologies.The urgent requirement to combat emerging infectious diseases contributes significantly to the growth prospects of the recombinant vaccines market in the UK. ### **Advancements in Vaccine Development Technology** Innovation in vaccine development technology is fundamentally reshaping the UK Recombinant Vaccines Market Industry. The recent advances in genetic engineering and recombinant DNA technology have enabled the rapid design and production of vaccines. The UK Biobank has reported substantial improvements in production efficiency, allowing for quicker responses to emerging health threats. For example, the development timelines for new vaccines have been significantly reduced.Corporations like GlaxoSmithKline are spearheading ventures in this area by integrating R&D processes and streamlining the introduction of recombinant vaccines. Improvements in methods of vaccine development also increase the developers’ confidence, alongside the stakeholders’ trust in its safety and effectiveness, which positively impacts growth in the market. ### **Government Initiatives and Funding for Vaccine Research** The UK government plays a vital role in supporting the recombinant vaccines sector through various initiatives and funding mechanisms. The Department of Health and Social Care has committed substantial resources towards research and development aimed at enhancing vaccine efficacy, which includes a budget increase of 15% towards immunization initiatives over recent years. Additionally, the UK Vaccine Network, established by the government, is working collaboratively with academia and industry to improve vaccine uptake and development.The commitment from established bodies such as the Wellcome Trust further underscores the UK government’s advocacy for recombinant vaccine research, fostering an environment conducive to innovation and market growth. ## **UK Recombinant Vaccines Market Segment Insights****:** ### **Recombinant Vaccines Market Product Insights** The UK Recombinant Vaccines Market exhibits a dynamic landscape characterized by its varied product offerings, including significant categories such as Subunit Recombinant and Attenuated Recombinant Vaccines. Subunit Recombinant Vaccines have gained traction due to their safety profile and effectiveness in generating targeted immune responses without introducing live pathogens, making them suitable for sensitive populations.  The increasing prevalence of infectious diseases, combined with advancements in biotechnology, has spurred the demand for this type of vaccine.Additionally, the UK government has recognized the potential of recombinant technologies, leading to increased funding in Research and Development initiatives aimed at enhancing vaccine efficacy. In contrast, Attenuated Recombinant Vaccines represent another vital component of the market, characterized by their ability to elicit robust and long-lasting immune responses. These vaccines utilize live microbes that have been weakened to trigger an immune response without causing disease.  Their importance is underscored by the successful deployment various vaccination programs, leading to significant public health outcomes.The segmentation of the UK Recombinant Vaccines Market is further influenced by the rising awareness of preventive healthcare and increasing investment in innovative vaccine technologies. Overall, these product segments reflect the ongoing evolution and adaptation within the UK healthcare landscape, driven by evolving disease challenges and the objective to enhance population immunity against various pathogens. As these segments evolve, they will increasingly play a pivotal role in shaping the future of immunization strategies in the UK. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Recombinant Vaccines Market Disease Insights** The UK Recombinant Vaccines Market, particularly in the Disease segment, has been evolving significantly, driven by advancements in biotechnology and a rising focus on disease prevention. This segment includes critical areas such as Cancer, Pneumococcal Disease, Hepatitis B, and DPT, each playing a vital role in public health initiatives across the UK. Cancer vaccines are experiencing increased attention due to their potential in preventing specific cancers, thereby reducing the healthcare burden. Pneumococcal vaccines are fundamental in combating pneumonia, which poses considerable mortality risk, especially among vulnerable populations. Hepatitis B vaccines have been crucial in curbing the spread of this viral infection, contributing to a safer community. Additionally, the DPT vaccine ensures robust defense against diphtheria, pertussis, and tetanus, diseases that can have severe implications if left unchecked. With growing awareness and government advocacy for vaccination, along with collaborative efforts in Research and Development, the UK Recombinant Vaccines Market continues to present opportunities for innovation and expansion within these vital areas, fostering better population health outcomes. ### **Recombinant Vaccines Market End-User Insights** The UK Recombinant Vaccines Market shows significant insights into the End-Users segment, which encompasses Pediatrics, Adults, and Veterinary applications. The expanding focus on immunization among pediatric populations is driven by various health initiatives aiming to reduce infectious disease prevalence. This segment remains crucial as children are particularly vulnerable to vaccine-preventable diseases, thus highlighting the importance of effective vaccine strategies in enhancing their health outcomes. Adults represent another key demographic, influenced by factors such as the rising incidence of chronic diseases and the increasing awareness of preventive healthcare measures. The emphasis on adult vaccination programs can lead to improved long-term health, contributing positively to public health goals. Furthermore, the Veterinary segment is gaining traction as pets and livestock are essential to both the economy and public health, emphasizing the need for effective vaccines to prevent zoonotic diseases. The UK government actively promotes immunization programs across all these demographics, thus creating a robust framework for growth opportunities driven by a combination of public health policies and rising awareness regarding vaccine benefits.The end-users will play a pivotal role in shaping the market landscape and driving future developments in the UK Recombinant Vaccines Market. ## **UK Recombinant Vaccines Market Key Players and Competitive Insights****:** The UK Recombinant Vaccines Market has become a focal point for biopharmaceutical development, driven by advancements in technology and an increasing focus on innovative therapeutic solutions. As recombinant vaccines play a critical role in preventing infectious diseases, their development has garnered attention from major pharmaceutical players.  The competitive landscape is characterized by a mix of established players and emerging companies competing through research and development, strategic partnerships, and regulatory navigation. There is a notable emphasis on innovative delivery systems and improved efficacy rates in the vaccines being produced, which further heightens the competition within this specialized market. Companies are leveraging their scientific expertise, along with financial investments, to enhance their positions and respond promptly to the public health needs related to infectious diseases that outline the importance of recombinant vaccines. Pfizer has established itself as a formidable player in the UK Recombinant Vaccines Market through its extensive portfolio of vaccine products with substantial efficacy. The company benefits from a strong brand reputation and a dedicated research and development infrastructure that allows it to innovate vigorously. Pfizer’s robust supply chain and experience in scaled manufacturing lend it an advantage, enabling efficient distribution and accessibility of its recombinant vaccines across the UK. Additionally, the company has formed strategic collaborations with various entities, enhancing its capacity to bring new vaccines to market swiftly.  The integration of advanced technologies and extensive clinical trial data further fortifies Pfizer’s presence in the market, allowing it to maintain a competitive edge by addressing health challenges with prompt and effective solutions.Biogen, although primarily recognized for its neurological and rare disease treatments, has been increasingly investing in the UK Recombinant Vaccines Market as part of its diversification strategy.  The company aims to leverage its biotechnical expertise to enhance vaccine efficacy and production capabilities. Key products and services related to vaccines have seen development as part of its growth initiatives, focusing on producing recombinant vaccines that target specific diseases prevalent in the UK. Biogen’s strategic mergers and acquisitions within the biotechnology space have positioned it to broaden its capabilities and enhance research efforts significantly. Its reputation for research excellence, coupled with collaborative efforts with governmental health organizations, allows Biogen to establish a credible presence in the recombinant vaccines market and contribute meaningfully to public health outcomes within the UK. ### **Key Companies in the UK Recombinant Vaccines Market Include:** - Pfizer - Biogen - Moderna - GlaxoSmithKline - Valneva - Regeneron Pharmaceuticals - Novartis - The Scripps Research Institute - Bayer - Vaxart - Johnson & Johnson - Sanofi Pasteur - AstraZeneca - Merck & Co - Sana Biotechnology ## **UK Recombinant Vaccines Market Industry Developments** The UK Recombinant Vaccines Market has seen significant activity recently, especially with companies like Pfizer, Moderna, and AstraZeneca leading advancements. In October 2023, Pfizer announced a partnership with the Scripps Research Institute to enhance vaccine development, focusing on innovative technologies that might boost efficacy against emerging strains. Meanwhile, Johnson and Johnson reported positive results from clinical trials of their latest recombinant vaccine. Growth in the market valuation of companies like Biogen and Valneva has been notable, driven by increasing investments in Research and Development for next-generation vaccines, particularly in the face of public health challenges. Moreover, in September 2023, Sanofi Pasteur completed a strategic acquisition of a biotech firm specializing in vaccine delivery systems, which is expected to enhance its operational capabilities. The UK government continues to support the sector's expansion through funding initiatives aimed at combatting vaccine hesitancy and increasing public awareness. The UK Recombinant Vaccines Market remains robust, fueled by strategic mergers, acquisitions, and a strong focus on collaborative research to address health issues. ## **UK Recombinant Vaccines Market Segmentation Insights** ### **Recombinant Vaccines Market Product****Outlook** - Subunit Recombinant - Attenuated Recombinant Vaccines ### **Recombinant Vaccines Market Disease****Outlook** - Cancer - Pneumococcal Disease - Hepatitis B - DPT ### **Recombinant Vaccines Market End-Users****Outlook** - Pediatrics - Adults - Veterinary ## Market Drivers ### Emerging Infectious Disease Threats The emergence of new infectious diseases poses a significant challenge to public health and is a key driver for the recombinant vaccines market. The UK has experienced outbreaks of various infectious diseases, highlighting the need for rapid vaccine development and deployment. The recombinant vaccines market is well-positioned to address these challenges, as these vaccines can be developed and produced more swiftly than traditional vaccines. The ability to respond quickly to emerging threats is crucial for maintaining public health safety. In light of recent epidemiological trends, the market is expected to expand as health authorities prioritize the development of vaccines targeting newly identified pathogens. This proactive approach may lead to an increase in funding and resources allocated to the recombinant vaccines market. ### Rising Demand for Preventive Healthcare The increasing emphasis on preventive healthcare in the UK is driving the recombinant vaccines market. As healthcare systems shift towards proactive measures, the demand for vaccines that can prevent diseases before they occur is likely to rise. This trend is supported by public health campaigns that advocate for vaccination as a primary strategy to reduce disease incidence. The recombinant vaccines market is expected to benefit from this shift, as these vaccines offer targeted protection against specific pathogens. Moreover, the UK government has allocated substantial funding towards vaccination programs, which may further stimulate market growth. In 2025, the market is projected to reach a valuation of approximately £1.5 billion, reflecting a compound annual growth rate (CAGR) of around 8% over the next five years. ### Increased Investment in Vaccine Research Investment in vaccine research and development is a critical driver for the recombinant vaccines market. The UK government, alongside private sector stakeholders, is committing substantial resources to advance vaccine technologies. This financial backing is essential for fostering innovation and accelerating the development of new recombinant vaccines. In recent years, funding for vaccine research has seen a notable increase, with estimates suggesting that public and private investments could exceed £500 million annually by 2026. This influx of capital is expected to enhance collaboration between academic institutions and industry players, leading to the rapid advancement of recombinant vaccine candidates. As a result, the market is likely to witness a surge in new product launches, catering to a broader range of infectious diseases. ### Advancements in Biopharmaceutical Technologies Technological innovations in biopharmaceuticals are significantly impacting the recombinant vaccines market. The development of novel expression systems and purification techniques has enhanced the efficiency and yield of vaccine production. These advancements not only reduce production costs but also improve the safety and efficacy profiles of vaccines. For instance, the use of mammalian cell lines for recombinant protein production has shown promising results in terms of post-translational modifications, which are crucial for vaccine effectiveness. As these technologies continue to evolve, they are likely to facilitate the introduction of new vaccines into the market, thereby expanding the range of available options for healthcare providers and patients alike. The recombinant vaccines market is poised for growth as these innovations are integrated into production processes. ### Growing Awareness of Vaccine Safety and Efficacy Public awareness regarding the safety and efficacy of vaccines is a pivotal factor influencing the recombinant vaccines market. As more individuals become informed about the benefits of vaccination, the demand for safe and effective vaccines is likely to increase. Educational initiatives and transparent communication from health authorities play a crucial role in building public trust. The recombinant vaccines market stands to gain from this heightened awareness, as these vaccines are often perceived as safer alternatives due to their targeted design and reduced risk of adverse reactions. In the UK, surveys indicate that approximately 75% of the population supports vaccination programs, which may translate into increased uptake of recombinant vaccines in the coming years. ## Future Outlook The [Recombinant Vaccines Market](https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130) is projected to grow at 16.51% CAGR from 2025 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments. **New opportunities:** - Development of personalized recombinant vaccines for niche markets. - Expansion of partnerships with biotech firms for innovative product pipelines. - Investment in advanced manufacturing technologies to enhance production efficiency. By 2035, the recombinant vaccines market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Subunit (Largest) vs. Vector (Fastest-Growing) In the UK recombinant vaccines market, the segment values exhibit distinct market share distributions. Subunit recombinant vaccines currently hold the largest market share due to their established safety profiles and efficacy in various applications, particularly in preventing infectious diseases. In contrast, attenuated recombinant vaccines are gaining traction but remain secondary in market share, while vector recombinant vaccines, although a newer concept, show increasing adoption rates. The growth trends within this segment highlight the rising investment in research and development of recombinant technologies. Factors driving this expansion include an increase in outbreaks requiring rapid vaccine development and rising public awareness about the benefits of recombinant vaccines. The flexibility of vector and subunit vaccines in addressing various pathogens is also propelling their growth, particularly in response to emerging infectious diseases. Subunit (Dominant) vs. Vector (Emerging) Subunit recombinant vaccines are characterized by their ability to stimulate strong immune responses with minimal adverse effects, making them the dominant player in the UK recombinant vaccines market. They utilize only specific pieces of the virus or bacteria, offering targeted protection while reducing the risk of disease. Conversely, vector recombinant vaccines are gaining attention as an emerging technology. They employ a harmless virus to deliver genetic material from a pathogen, encouraging the host’s immune system to recognize and respond to it. This innovative approach drives versatility and enhances the potential for rapid response to emerging threats, positioning vector vaccines as a significant competitor in the evolving market landscape. ### By Disease: Pneumococcal Disease (Largest) vs. Cancer (Fastest-Growing) In the UK recombinant vaccines market, the distribution of market share among various diseases showcases a diversified landscape. Pneumococcal Disease remains the largest segment, buoyed by high vaccination rates and public health initiatives aimed at reducing morbidity and mortality associated with the disease. Following closely, Cancer vaccines represent a significant portion of the market, reflecting the growing emphasis on preventive care and the increasing prevalence of various cancers in the population. Growth trends indicate that while Pneumococcal Disease continues to hold a strong position, Cancer vaccines are emerging as the fastest-growing segment due to advancements in technology and increased funding for research and development. The heightened awareness of cancer prevention through vaccines is driving demand, alongside robust government support for innovative therapies. This trend is expected to persist, further shaping the competitive dynamics of the market in the coming years. Pneumococcal Disease: Dominant vs. Cancer: Emerging Pneumococcal Disease vaccines dominate the UK recombinant vaccines market, primarily due to their widespread use in immunization programs targeting vulnerable populations, including children and the elderly. These vaccines are critical for preventing pneumonia and other related diseases, resulting in significant public health benefits. In contrast, Cancer vaccines are emerging as a promising area of growth, propelled by scientific advancements and the increasing prioritization of cancer prevention strategies. With a focus on developing vaccines specific to various cancer types, this segment is witnessing rapid innovation and investment, making it a key player for future developments in the market. Both segments reflect the evolving landscape of healthcare, emphasizing the importance of vaccination as a preventive measure. ### By End-User: Hospitals & Clinics (Largest) vs. Veterinary (Fastest-Growing) In the UK recombinant vaccines market, the distribution of market share among the end-user segments reveals that Hospitals & Clinics account for the largest portion, driven by the increasing adoption of advanced healthcare practices and robust immunization programs. Following closely are segments like Pediatrics and Adults, which are significant contributors due to heightened awareness regarding vaccination benefits and government initiatives promoting vaccination campaigns. Veterinary and Agriculture sectors, including Poultry and Livestock, are also gaining traction, albeit at a slower pace compared to human health segments. Growth trends indicate that the Hospitals & Clinics segment is supported by ongoing investments in healthcare infrastructure and emerging infectious disease threats. Meanwhile, Veterinary and Poultry segments are witnessing a surge, attributed to rising livestock farming practices and the need for disease control in animal populations. The increasing emphasis on biosecurity and animal health management further fuels demand within these segments, making them key drivers of overall market growth in the foreseeable future. Hospitals & Clinics (Dominant) vs. Veterinary (Emerging) Hospitals & Clinics represent the dominant force in the UK recombinant vaccines market, largely benefiting from established healthcare systems and significant investments in medical research and public health initiatives. This segment showcases a stringent adherence to vaccination protocols, which ensures a steady uptake of vaccines. In contrast, the Veterinary segment is emerging swiftly, particularly due to an increase in awareness concerning animal health and the importance of vaccinations in preventing diseases among livestock and pets. This growth is spurred by rising animal husbandry activities and the ongoing development of new veterinary vaccines tailored to address specific zoonotic diseases. Consequently, both segments play pivotal roles, with Hospitals & Clinics setting the pace while Veterinary develops in response to market needs. ## Competitive Benchmarking The recombinant vaccines market is currently characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on regional expansion. Key players such as Pfizer (US), GSK (GB), and Sanofi (FR) are actively shaping the market through their distinct operational strategies. Pfizer (US) has positioned itself as a leader in mRNA technology, emphasizing rapid development and deployment capabilities. GSK (GB) is focusing on enhancing its vaccine portfolio through collaborations and investments in research and development, while Sanofi (FR) is leveraging its extensive global network to expand access to its recombinant vaccine offerings. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and market responsiveness.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players exerting influence over specific segments. This fragmentation allows for a diverse range of products and innovations, although it also necessitates strategic collaborations among companies to maintain competitive advantages and meet evolving consumer demands. In October GSK (GB) announced a strategic partnership with a leading biotechnology firm to co-develop a novel recombinant vaccine targeting emerging infectious diseases. This collaboration is significant as it not only enhances GSK's research capabilities but also positions the company to respond more effectively to future health threats. The partnership underscores the importance of agility and innovation in the current market landscape. In September Pfizer (US) launched a new initiative aimed at increasing the accessibility of its recombinant vaccines in underserved regions of the UK. This initiative is crucial as it reflects Pfizer's commitment to equitable healthcare and its recognition of the need for localized solutions. By enhancing access, Pfizer is likely to strengthen its market position and foster goodwill among healthcare providers and patients alike. In August Sanofi (FR) expanded its manufacturing capabilities in the UK, investing €100 million in a new facility dedicated to recombinant vaccine production. This expansion is indicative of Sanofi's long-term commitment to the UK market and its strategy to enhance production capacity in response to growing demand. Such investments are likely to bolster Sanofi's competitive edge and ensure a reliable supply of vaccines. As of November current trends in the recombinant vaccines market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach market entry and product development, ultimately benefiting consumers through enhanced vaccine offerings. ## Recent News & Developments The UK Recombinant Vaccines Market has seen significant activity recently, especially with companies like Pfizer, Moderna, and AstraZeneca leading advancements. In October 2023, Pfizer announced a partnership with the Scripps Research Institute to enhance vaccine development, focusing on innovative technologies that might boost efficacy against emerging strains. Meanwhile, Johnson and Johnson reported positive results from clinical trials of their latest recombinant vaccine. Growth in the market valuation of companies like Biogen and Valneva has been notable, driven by increasing investments in Research and Development for next-generation vaccines, particularly in the face of public health challenges. Moreover, in September 2023, Sanofi Pasteur completed a strategic acquisition of a biotech firm specializing in vaccine delivery systems, which is expected to enhance its operational capabilities. The UK government continues to support the sector's expansion through funding initiatives aimed at combatting vaccine hesitancy and increasing public awareness. The UK Recombinant Vaccines Market remains robust, fueled by strategic mergers, acquisitions, and a strong focus on collaborative research to address health issues. ## Report Scope | MARKET SIZE 2024 | 13.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 15.73(USD Million) | | MARKET SIZE 2035 | 72.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.51% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Moderna (US), Sanofi (FR), Merck (US), GSK (GB), Novavax (US), Bavarian Nordic (DK), Zydus Cadila (IN), Serum Institute of India (IN) | | Segments Covered | Type, Disease, End-User | | Key Market Opportunities | Advancements in genetic engineering enhance efficacy and safety in the recombinant vaccines market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the recombinant vaccines market, enhancing competitive dynamics. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK recombinant vaccines market?** A: The overall market valuation was $13.5 Million in 2024. **Q: What is the projected market valuation for the UK recombinant vaccines market in 2035?** A: The projected valuation for 2035 is $72.5 Million. **Q: What is the expected CAGR for the UK recombinant vaccines market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 16.51%. **Q: Which companies are the key players in the UK recombinant vaccines market?** A: Key players include Pfizer, Moderna, Sanofi, Merck, GSK, Novavax, Bavarian Nordic, Zydus Cadila, and Serum Institute of India. **Q: What are the different types of recombinant vaccines in the market?** A: The market segments include subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. **Q: How did the subunit recombinant vaccines perform in 2024?** A: In 2024, subunit recombinant vaccines were valued at $3.5 Million. **Q: What is the market size for vector recombinant vaccines projected for 2035?** A: The market size for vector recombinant vaccines is projected to reach $24.0 Million by 2035. **Q: Which diseases are targeted by recombinant vaccines in the UK market?** A: Diseases targeted include pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others. **Q: What was the market valuation for influenza vaccines in 2024?** A: The market valuation for influenza vaccines was $3.0 Million in 2024. **Q: What are the end-user segments for recombinant vaccines in the UK market?** A: End-user segments include hospitals & clinics, pediatrics, adults, veterinary, poultry, livestock, and others. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-recombinant-vaccines-market-56005*